The Double Homeobox Protein 4 pipeline drugs market research report outlays comprehensive information on the Double Homeobox Protein 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Double Homeobox Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Musculoskeletal Disorders which include the indications Facioscapulohumeral Muscular Dystrophy (FSHD). It also reviews key players involved in Double Homeobox Protein 4 targeted therapeutics development with respective active and dormant or discontinued products.

The Double Homeobox Protein 4 pipeline targets constitutes close to 16 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 8, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 2 molecule.

Double Homeobox Protein 4 overview

Double homeobox protein 4 (DUX4) is a transcription factor that is selectively and transiently expressed in cleavage-stage embryos. It binds to double-stranded DNA elements with the consensus sequence 5′-TAATCTAATCA-3′, and to chromatin containing histone H3 acetylated at ‘Lys-27’ (H3K27ac) and promotes deacetylation of H3K27ac. In parallel, it binds to chromatin that lacks histone H3 acetylation at ‘Lys-27’ (H3K27ac) and recruits EP300 and CREBBP to promote acetylation of histone H3 at ‘Lys-27’ at new sites.

For a complete picture of Double Homeobox Protein 4’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.